BioInfect

R&D

When is the superbug message going to bite?

As existing antibiotics become less effective, we edge closer to a future where routine infections & minor injuries could once again become high risk.

Patients

Houses of Parliament - a Labour government

Labour, the NHS, and life sciences: Partnerships and people

The United Kingdom this morning woke to landslide poll results: Labour is in on just 34% of the vote following the worst Conservative defeat in the party’s history.

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks